Digital Content 
NEWS #PharmaBuzz
16 Nov 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-syndaxs-blood-cancer-drug-2024-11-15/
12 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/syndax-announces-publication-in-the-journal-of-clinical-oncology-of-data-from-the-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-302219402.html
29 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/syndax-announces-pdufa-action-date-extension-for-revumenib-nda-for-relapsed-or-refractory-kmt2ar-acute-leukemia-302208308.html
14 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/syndax-presents-updated-positive-data-from-beat-aml-and-augment-102-phase-12-combination-trials-of-revumenib-in-patients-with-acute-leukemias-at-eha-2024-congress-302172942.html
06 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/syndax-announces-plans-to-advance-into-phase-1b-portion-of-trial-evaluating-revumenib-in-relapsed-or-refractory-metastatic-mss-crc-302165405.html
08 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/syndax-presents-positive-pediatric-data-from-pivotal-augment-101-trial-of-revumenib-in-relapsedrefractory-kmt2ar-acute-leukemia-at-aspho-plenary-session-302109899.html
LOOKING FOR A SUPPLIER?
Share